Is there a role for macrolides in severe asthma?

Area of Science:

• Respiratory Medicine
• Pharmacology
• Clinical Immunology

Background:

• Severe asthma is a complex condition with diverse underlying inflammation types (endotypes).
• Understanding these endotypes is crucial for effective treatment strategies.
• Macrolides are antibiotics with anti-inflammatory properties being explored for severe asthma.

Purpose of the Study:

• To review the potential role of macrolide therapy in managing severe asthma in adults.
• To examine macrolide efficacy in different severe asthma endotypes.
• To discuss the risks and benefits of long-term macrolide use in severe asthma.

Main Methods:

• Review of existing literature on macrolide use in airway diseases.
• Analysis of clinical trial data, including the AzIthromycin in Severe Asthma trial.
• Discussion of pharmacological mechanisms and resistance concerns.

Main Results:

• Low-dose macrolides show clinical benefit in chronic neutrophilic airway diseases.
• The AzIthromycin in Severe Asthma trial indicated reduced exacerbations in noneosinophilic severe asthma.
• Short-term macrolide studies in mild-to-moderate asthma did not improve lung function.

Conclusions:

• Macrolide maintenance treatment may be beneficial for specific severe asthma phenotypes, particularly neutrophilic types.
• Antimicrobial resistance is a significant concern, limiting macrolide use to patients with high unmet needs.
• Further research is required to optimize patient selection and understand macrolide mechanisms in severe asthma.